32 results on '"Galanti, D"'
Search Results
2. Lapatinib activity in a patient with encephalic metastases from trastuzumab-resistant her-2 positive breast cancer
- Author
-
Galanti D., Vaccaro G., Cipolla C., Graceffa G., Valerio M. R., Galanti D., Vaccaro G., Cipolla C., Graceffa G., and Valerio M.R.
- Subjects
breast cancer ,Lapatinib ,metastases - Abstract
A 42-year-old woman with right breast cancer cT4dN2M0 HR +, HER2 +, undergoes mastectomy with axillary lymphadenectomy after neoadjuvant chemotherapy. During adjuvant treatment with trastuzumab and hormone therapy, the patient develops multiple symptomatic encephalic metastases. She undergoes panencephalic radiotherapy and begins chemotherapy with capecitabine and lapatinib. After three months of well tolerated therapy, an important volumetric response of encephalic metastases is observed, with regression of neurological symptoms.
- Published
- 2020
3. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
- Author
-
Cazzaniga, M, Pinotti, G, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Fiorentini, G, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Melegari, E, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cicchiello, F, Riva, F, Vallini, I, Mazza, M, Bonfadini, C, Bordin, E, Canicatti, M, Cappuccio, F, Collova, E, De Angelis, C, Desorte, R, Donati, S, Drudi, G, Galanti, D, Mocerino, C, Orlando, L, Pellegrino, B, Pizzuti, L, Ridolfi, C, Rocca, A, Sarti, D, Spagnoletti, I, Tinari, N, Vandone, A, Vizzini, L, Cazzaniga M. E., Pinotti G., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Fiorentini G., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Melegari E., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cicchiello F., Riva F., Vallini I., Mazza M., Bonfadini C., Bordin E., Canicatti M., Cappuccio F., Collova E., De Angelis C., Desorte R., Donati S., Drudi G., Galanti D., Mocerino C., Orlando L., Pellegrino B., Pizzuti L., Ridolfi C., Rocca A., Sarti D., Spagnoletti I., Tinari N., Vandone A., Vizzini L., Cazzaniga, M, Pinotti, G, Montagna, E, Amoroso, D, Berardi, R, Butera, A, Cagossi, K, Cavanna, L, Ciccarese, M, Cinieri, S, Cretella, E, De Conciliis, E, Febbraro, A, Ferrau, F, Ferzi, A, Fiorentini, G, Fontana, A, Gambaro, A, Garrone, O, Gebbia, V, Generali, D, Gianni, L, Giovanardi, F, Grassadonia, A, Leonardi, V, Marchetti, P, Melegari, E, Musolino, A, Nicolini, M, Putzu, C, Riccardi, F, Santini, D, Saracchini, S, Sarobba, M, Schintu, M, Scognamiglio, G, Spadaro, P, Taverniti, C, Toniolo, D, Tralongo, P, Turletti, A, Valenza, R, Valerio, M, Vici, P, Clivio, L, Torri, V, Cicchiello, F, Riva, F, Vallini, I, Mazza, M, Bonfadini, C, Bordin, E, Canicatti, M, Cappuccio, F, Collova, E, De Angelis, C, Desorte, R, Donati, S, Drudi, G, Galanti, D, Mocerino, C, Orlando, L, Pellegrino, B, Pizzuti, L, Ridolfi, C, Rocca, A, Sarti, D, Spagnoletti, I, Tinari, N, Vandone, A, Vizzini, L, Cazzaniga M. E., Pinotti G., Montagna E., Amoroso D., Berardi R., Butera A., Cagossi K., Cavanna L., Ciccarese M., Cinieri S., Cretella E., De Conciliis E., Febbraro A., Ferrau F., Ferzi A., Fiorentini G., Fontana A., Gambaro A. R., Garrone O., Gebbia V., Generali D., Gianni L., Giovanardi F., Grassadonia A., Leonardi V., Marchetti P., Melegari E., Musolino A., Nicolini M., Putzu C., Riccardi F., Santini D., Saracchini S., Sarobba M. G., Schintu M. G., Scognamiglio G., Spadaro P., Taverniti C., Toniolo D., Tralongo P., Turletti A., Valenza R., Valerio M. R., Vici P., Clivio L., Torri V., Cicchiello F., Riva F., Vallini I., Mazza M., Bonfadini C., Bordin E., Canicatti M., Cappuccio F., Collova E., De Angelis C., Desorte R., Donati S., Drudi G., Galanti D., Mocerino C., Orlando L., Pellegrino B., Pizzuti L., Ridolfi C., Rocca A., Sarti D., Spagnoletti I., Tinari N., Vandone A., and Vizzini L.
- Abstract
Metronomic chemotherapy (mCHT) refers to the minimum biologically effective dose of a chemotherapy agent given as a continuous dosing regimen, with no prolonged drug-free breaks, that leads to antitumor activity. Aim of the present study is to describe the use of mCHT in a retrospective cohort of metastatic breast cancer (MBC) patients in order to collect data regarding the different types and regimens of drugs employed, their efficacy and safety. Between January 2011 and December 2016, data of 584 metastatic breast cancer patients treated with mCHT were collected. The use of VRL-based regimens increased during the time of observation (2011: 16.8% - 2016: 29.8%), as well as CTX-based ones (2011: 17.1% - 2016: 25.6%), whereas CAPE-based and MTX-based regimens remained stable. In the 1st-line setting, the highest ORR and DCR were observed for VRL-based regimens (single agent: 44% and 88%; combination: 36.7% and 82.4%, respectively). Assuming VRL-single agent as the referee treatment (median PFS: 7.2 months, 95% CI: 5.3–10.3), the longest median PFS were observed in VRL-combination regimens (9.5, 95%CI 88.8–11.3, HR = 0.72) and in CAPE-single agent (10.7, 95%CI 8.3–15.8, HR = 0.70). The VICTOR-6 study provides new data coming from the real-life setting, by adding new information regarding the use of mCHT as an option of treatment for MBC patients.
- Published
- 2019
4. Personalizing Cancer Pain Therapy: Insights from the Rational Use of Analgesics (RUA) Group
- Author
-
Varrassi, G., Coluzzi, F., Guardamagna, V. A., Puntillo, F., Sotgiu, G., Vellucci, R., Abrardi, L., Aiello, A., Albanese, G. V., Alongi, A., Altavilla, L., Ambrosio, R., Ammirati, L. A., Bacchini, G. P., Balbi, V., Ballarin, S., Balloni, A. G., Bambagioni, V., Bellavia, G., Berte', R., Bertolini, F., Bertolucci, A., Bilani, V., Bonafede, E. V., Bonato, C., Bondi, F., Bosco, M., Bottino, F., Branca, B., Brizio, A., Brogi, L., Brollo, M., Bruera, G., Brusco, G., Burato, A. M., Caiozzi, S. F., Calabrese, G., Calligaris, M., Cantisani, E., Capecchi, S., Caponi, S., Carbone, M., Carella, C., Careri, M. C., Carnicella, A., Caruso, M. L., Catania, E., Cavo, A., Cianci, G., Cocchiarella, A., Colombo, L., Corsi, G., Cortinovis, R., Costantini, S., Crispi, M., Cuccu, G., Cuomo, A., Dalia, P., D'Amato, G., De Chirico, C., De Clementi, M., De Gasperi, M., De Lisi, A., De Lucia, L., De Martino, G., De Toni, P., De Tursi, M., Defendi, S., Degl'Innocenti, M., Santi, I. D., Destro, M., Di Bartolomeo, C., Di Ciaula, G., Di Fonzo, C., Di Maggio, G., Di Matteo, S., Di Paolo, A., Di Trapani, M. C., Di Zio, I., Diodati, M., Dongiovanni, D., D'Urso, M., Fabiani, M. G., Facciuto, P., Falco, V., Faraone, E., Fasano, M., Ferrara, P., Florian, C., Fora, G., Fornaro, F., Forno, B., Fortis, M., Foti, S., Friolo, D., Gabris, A., Galanti, D., Galizia, B., Gallo, P., Gaudio, L., Gentili, G., Ginex, G., Giuliani, J., Gobber, G., Amerelli, A. G., Gorgni, S., Gucciardino, C., Ieri, T., Ingui', M., Jamara, G., La Sala, A., Lattuca, P., Mauro, M. L., Luigini, A., Luisi, D., Lungu, V., Mabilia, R., Macaluso, S., Maglio, A., Magnapera, A., Maione, A., Malorgio, F., Mancuso, A., Manni, A., Marchesi, R., Mariani, M., Martini, A., Massetti, M., Mauceri, M., Melo, M., Merlotti, R., Modugno, D., Montagna, M. C., Montanari, L., Napolitano, G., Nicodemo, M., Orlandini, G., Orlandini, F., Orsi, P., Pacifico, C., Pagliaro, E., Paladini, A., Paolucci, V., Pascazio, A., Pastore, A., Patanella, I., Pedaci, E., Pellegrini, A., Pellerito, N., Pepe, V., Petreni, P., Piazza, S., Picchi, M., Piccinelli, G., Pignatelli, A., Pinta, F., Pinto, T., Piovano, P. L., Pirajno, G., Pollastrini, C., Potenza, I., Provenzano, A., Provinciali, N., Puglia, L., Putignano, D., Ranucci, A., Ravoni, G., Redivo, L., Ricchini, F., Rizzi, F., Romoli, M., Ronga, G., Rosafio, I., Roselli, L., Russano, M., Russo, P., Saetta, A., Sarnelli, R., Sartori, S., Saviola, A., Scandone, F., Scibilia, C., Silverj, E., Sosta, E., Sparacino, M. E., Tavella, E., Tempera, S., Terranova, A., Tomasini, V., Trivellato, E., Vallisneri, C., Vannini, A., Vassillo, M., Verni, P., Visconti, E., Zaza, A., and Zizzetti, S.
- Subjects
medicine.medical_specialty ,Palliative care ,business.industry ,Pain medicine ,Breakthrough pain ,Cancer pain ,Opioid-induced bowel dysfunction (OIBD) ,Opioid-induced constipation (OIC) ,Opioids ,Delphi method ,Likert scale ,Anesthesiology and Pain Medicine ,Opioid ,Multidisciplinary approach ,Interquartile range ,Family medicine ,Medicine ,Neurology (clinical) ,business ,medicine.drug - Abstract
A previous Delphi survey from the Rational Use of Analgesics (RUA) project involving Italian palliative care specialists revealed some discrepancies between current guidelines and clinical practice with a lack of consensus on items regarding the use of strong opioids in treating cancer pain. Those results represented the basis for a new Delphi study addressing a better approach to pain treatment in patients with cancer. The study consisted of a two-round multidisciplinary Delphi study. Specialists rated their agreement with a set of 17 statements using a 5-point Likert scale (0 = totally disagree and 4 = totally agree). Consensus on a statement was achieved if the median consensus score (MCS) (expressed as value at which at least 50% of participants agreed) was at least 4 and the interquartile range (IQR) was 3–4. This survey included input from 186 palliative care specialists representing all Italian territory. Consensus was reached on seven statements. More than 70% of participants agreed with the use of low dose of strong opioids in moderate pain treatment and valued transdermal route as an effective option when the oral route is not available. There was strong consensus on the importance of knowing opioid pharmacokinetics for therapy personalization and on identifying immediate-release opioids as key for tailoring therapy to patients’ needs. Limited agreement was reached on items regarding breakthrough pain and the management of opioid-induced bowel dysfunction. These findings may assist clinicians in applying clinical evidence to routine care settings and call for a reappraisal of current pain treatment recommendations with the final aim of optimizing the clinical use of strong opioids in patients with cancer.
- Published
- 2021
5. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study
- Author
-
Cazzaniga, M.E., primary, Pinotti, G., additional, Montagna, E., additional, Amoroso, D., additional, Berardi, R., additional, Butera, A., additional, Cagossi, K., additional, Cavanna, L., additional, Ciccarese, M., additional, Cinieri, S., additional, Cretella, E., additional, De Conciliis, E., additional, Febbraro, A., additional, Ferraù, F., additional, Ferzi, A., additional, Fiorentini, G., additional, Fontana, A., additional, Gambaro, A.R., additional, Garrone, O., additional, Gebbia, V., additional, Generali, D., additional, Gianni, L., additional, Giovanardi, F., additional, Grassadonia, A., additional, Leonardi, V., additional, Marchetti, P., additional, Melegari, E., additional, Musolino, A., additional, Nicolini, M., additional, Putzu, C., additional, Riccardi, F., additional, Santini, D., additional, Saracchini, S., additional, Sarobba, M.G., additional, Schintu, M.G., additional, Scognamiglio, G., additional, Spadaro, P., additional, Taverniti, C., additional, Toniolo, D., additional, Tralongo, P., additional, Turletti, A., additional, Valenza, R., additional, Valerio, M.R., additional, Vici, P., additional, Clivio, L., additional, Torri, V., additional, Cicchiello, F., additional, Riva, F., additional, Vallini, I., additional, Mazza, M., additional, Bonfadini, C., additional, Bordin, E., additional, Canicattì, M., additional, Cappuccio, F., additional, Collovà, E., additional, De Angelis, C., additional, Desorte, R., additional, Donati, S., additional, Drudi, G., additional, Galanti, D., additional, Mocerino, C., additional, Orlando, L., additional, Pellegrino, B., additional, Pizzuti, L., additional, Ridolfi, C., additional, Rocca, A., additional, Sarti, D., additional, Spagnoletti, I., additional, Tinari, N., additional, Vandone, A., additional, and Vizzini, L., additional
- Published
- 2019
- Full Text
- View/download PDF
6. Radiofrequency thermoablation (RFA) and radiotherapy (RT) combined treatment for bone metastases: a systematic review.
- Author
-
PIRAS, A., LA VECCHIA, M., BOLDRINI, L., D'AVIERO, A., GALANTI, D., GUARINI, A., SANFRATELLO, A., VENUTI, V., ANGILERI, T., and DAIDONE, A.
- Abstract
OBJECTIVE: Approximately 50% of cancer patients develop bone metastases in their natural disease history. The management of metastatic bone disease requires a multidisciplinary approach. Both radiofrequency ablation (RFA) and radiation therapy (RT) were safe and effective in the management of painful metastases, even if they rely on totally different action mechanisms. A synergistic combination of RT and RFA seems to result in a better pain control. A systematic review was performed to describe the feasibility and effectiveness of the association between RFA and RT in the treatment of metastatic bone pain in oligo-metastatic patients, evaluating its role in alleviating bone pain, reducing the risk of fractures, and consequently ensuring a better quality of life. MATERIALS AND METHODS: A systematic database search was conducted according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. This systematic review included studies that reported populations meeting the following inclusion criteria: (I) confirmed bone metastases in adult patients; (II) active bone metastases pain; (III) patients treated with combined RFA-RT; (IV) Original studies. RESULTS: Three papers that evaluated the combined treatment with doses ranging from moderately hypofractionated three-dimensional conformal RT (3D-CRT) and stereotactic body radiation therapy (SBRT) schedules were selected. CONCLUSIONS: The RFA-RT combined strategy appears to be promising in terms of efficiency and safety with adequate pain control and quality of life improvement. Positive effects on time to local failure and overall survival increase were also observed. Further prospective studies are needed to better delineate RFA-RT treatment benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2021
7. Transición al cuidado de la vida adulta, de niños y adolescentes con necesidades especiales de atención en salud: recomendaciones del comité NANEAS de la Sociedad Chilena de Pediatría
- Author
-
Nelson A Vargas C, Mónica Galanti D, Mario Varela G, Macarena Lizama C, Carmen Luz Navarrete S, María E Ávalos A, and Jorge Orellana W
- Subjects
Gerontology ,business.industry ,adolescentes ,Transición ,Special health care needs ,Infant mortality ,Health personnel ,Nursing ,Intensive care ,necesidades especiales ,Pediatrics, Perinatology and Child Health ,Medicine ,enfermedades crónicas ,Pediatric care ,business ,Adult health - Abstract
La medicina en el mundo ha evolucionado y Chile no se ha quedado fuera de esta realidad. Los avances en las terapias para enfermedades crónicas, los avances en unidades de neonatología y cuidados críticos, han conseguido que muchos niños sobrevivan, mejorando las tasas de mortalidad infantil, pero con un aumento en el número de niños y adolescentes con enfermedades crónicas y necesidades especiales de atención en salud. El cuidado pediátrico de este grupo de niños y adolescentes ha sufrido un desarrollo en los últimos años, sin embargo, el traspaso a los cuidados del adulto con necesidades especiales es una experiencia dificultosa para el paciente, su familia y los equipos de salud. El propósito de este documento es entregar y proponer recomendaciones a las autoridades y al personal de salud de Chile, que faciliten un adecuado y saludable traspaso de los cuidados desde el equipo pediátrico al de equipos que atienden adultos, lo que es llamado "Transición".
- Published
- 2011
- Full Text
- View/download PDF
8. Role of Anaplus HP in prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients affected by breast cancer treated with taxane-based adjuvant chemotherapy
- Author
-
La Vecchia, M., primary, Galanti, D., additional, Volpe, C., additional, and Valerio, M.R., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Micetrin to prevent chemotherapy-induced nausea and fatigue in adjuvant treatment of breast cancer
- Author
-
Galanti, D., primary, La Vecchia, M., additional, Catarella, M.T., additional, Crosta, L., additional, and Valerio, M.R., additional
- Published
- 2017
- Full Text
- View/download PDF
10. Methotrexate chemotherapy in elderly patients with locally advanced head and neck cancer: preliminary results
- Author
-
Rinaldi, G., primary, Galanti, D., additional, Stagno, A., additional, Bronte, E., additional, Marchese, A., additional, Badalamenti, G., additional, Semprevivo, M., additional, Terruso, L., additional, Vanella, V., additional, Alessi, I., additional, Fulfaro, F., additional, Malfitano, A., additional, Cordova, A., additional, Albanese, V., additional, Volpe, C., additional, Incorvaia, L., additional, and Russo, A., additional
- Published
- 2016
- Full Text
- View/download PDF
11. S13 - Micetrin to prevent chemotherapy-induced nausea and fatigue in adjuvant treatment of breast cancer
- Author
-
Galanti, D., La Vecchia, M., Catarella, M.T., Crosta, L., and Valerio, M.R.
- Published
- 2017
- Full Text
- View/download PDF
12. S12 - Role of Anaplus HP in prevention of chemotherapy-induced peripheral neuropathy (CIPN) in patients affected by breast cancer treated with taxane-based adjuvant chemotherapy
- Author
-
La Vecchia, M., Galanti, D., Volpe, C., and Valerio, M.R.
- Published
- 2017
- Full Text
- View/download PDF
13. Epidemiología molecular de un brote de infecciones por Streptococcus pyogenes en una unidad de quemados
- Author
-
Catalina Alonso M, Ana María Frola M, María Teresa Ulloa F, Soledad Prat M., Erna Cona T, Germán Ebensperger D, Andrea Galanti D, Jorge Fernández O, and Alberto Fica C
- Subjects
Molecular epidemiology ,Streptococcus pyogenes ,Outbreak ,Toxic shock syndrome ,General Medicine ,Biology ,medicine.disease_cause ,medicine.disease ,Group A ,RAPD ,Microbiology ,law.invention ,law ,Molecular sequence data ,medicine ,Pulsed-field gel electrophoresis ,Molecular probe technics ,Disease outbreaks ,Polymerase chain reaction - Abstract
Group A Streptococcal (GAS) infections have increased in frequency and severity worldwide. During April 1996, a nosocomial outbreak associated to GAS infections affected seven patients admitted to a pediatric burn unit. The causative organism was likely disseminated from the source patient to another child in the emergency room before he was transferred to the burn unit. Patients developed burn infections or invasive disease. One of them died due to a toxic shock syndrome and 3 other lost their skin grafts. Perineal and nasal microbiological surveillance of 42 related health care workers identified only one of them as carrier of S pyogenes. Aim: To report a molecular analysis of an apparently clonal outbreak. Material and methods: The available isolates were analyzed by molecular methods including random amplified polymorphic DNA analysis (RAPD) with 4 different primers, Sma-I pulsed field gel electrophoresis (PFGE) analysis, and speA, speB and speC detection by polymerase chain reaction (PCR). Results: Two phylogenetically distant and sequentially isolated bacterial groups were identified either by RAPD analysis with selected primers or by Smal-PFGE analysis. The first group involved isolates identified in two patients that included the lethal case. The second bacterial group comprised 5 clinical isolates and the perineal and nasal isolates obtained from a health care worker. Only strains belonging to the first group harbored the speA gene and were associated with invasive disease. The second group could be split further in two subgroups according to their speB profile. Conclusions: RAPD analysis with selected primers can reproduce the PFGE-discriminating ability on the epidemiological analysis of GAS infections (Rev Med Chile 2003; 131: 145-54)
- Published
- 2003
14. L13 - Methotrexate chemotherapy in elderly patients with locally advanced head and neck cancer: preliminary results
- Author
-
Rinaldi, G., Galanti, D., Stagno, A., Bronte, E., Marchese, A., Badalamenti, G., Semprevivo, M., Terruso, L., Vanella, V., Alessi, I., Fulfaro, F., Malfitano, A., Cordova, A., Albanese, V., Volpe, C., Incorvaia, L., and Russo, A.
- Published
- 2016
- Full Text
- View/download PDF
15. Transición al cuidado de la vida adulta, de niños y adolescentes con necesidades especiales de atención en salud: recomendaciones del comité NANEAS de la Sociedad Chilena de Pediatría
- Author
-
LIZAMA C, MACARENA, primary, ÁVALOS A, MARÍA E, additional, VARGAS C, NELSON A, additional, VARELA G, MARIO A, additional, NAVARRETE S, CARMEN L, additional, GALANTI D, MÓNICA, additional, and ORELLANA W, JORGE, additional
- Published
- 2011
- Full Text
- View/download PDF
16. Epidemiología molecular de un brote de infecciones por Streptococcus pyogenes en una unidad de quemados
- Author
-
Fica C, Alberto, primary, Fernández O, Jorge, additional, Ebensperger D, Germán, additional, Cona T, Erna, additional, Galanti D, Andrea, additional, Alonso M, Catalina, additional, Ulloa F, María Teresa, additional, Frola M, Ana María, additional, and Prat M, Soledad, additional
- Published
- 2003
- Full Text
- View/download PDF
17. NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience
- Author
-
Maria La Vecchia, Salvatore Pardo, D Galanti, Vittorio Gebbia, Vincenzo Serretta, Calogero Cipolla, Nicolò Borsellino, Maria Rosaria Valerio, Valerio M.R., Gebbia V., Borsellino N., Vecchia M.L., Serretta V., Pardo S., Cipolla C., and Galanti D.
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Nausea ,medicine.drug_class ,medicine.medical_treatment ,Ondansetron ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Antiemetic ,Pharmacology (medical) ,carboplatin, Chemotherapy-induced nausea and vomiting, gemcitabine, netupitant, NSCLC, ondansetron, ovarian cancer, palonosetron, urothelial cancer, dexamethasone ,Chemotherapy ,business.industry ,Gemcitabine ,Carboplatin ,030104 developmental biology ,chemistry ,030220 oncology & carcinogenesis ,Vomiting ,medicine.symptom ,business ,medicine.drug ,Chemotherapy-induced nausea and vomiting - Abstract
Introduction Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients’ quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK1-RA and palonosetron, a 5HT3-RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist. Methods Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastatic non-small cell lung cancer (NSCLC), ovarian cancer or urothelial cancer and experienced nausea and/or vomiting after the first cycle of chemotherapy, despite an antiemetic prophylaxis with a 5HT3-RA and dexamethasone. Primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) obtained with NEPA, during the overall phase (0–120 h), after the start of chemotherapy. Results During the first cycle of chemotherapy, 15 out of 30 (50%) patients did not properly control CINV with a 5HT3-RA plus dexamethasone used as primary antiemetic prophylaxis and then were switched to NEPA from the subsequent cycle. During NEPA administration, 13 out of 15 patients (86.7%) achieved an overall CR (no emesis, no rescue medication). Antiemetic treatment with NEPA was very well tolerated with only two patients (13.3%) that experienced a grade 1 TEAE. Conclusions Our experience showed that NEPA has proven to be very effective and well tolerated in the prophylaxis of CINV induced by carboplatin-based chemotherapy.
- Published
- 2020
18. Current treatment options for HER2-positive breast cancer patients with brain metastases
- Author
-
Alessandro Inno, Antonio Russo, Maria La Vecchia, Nicolò Borsellino, Stefania Gori, Lorena Incorvaia, Daniele Galanti, Galanti D., Inno A., La Vecchia M., Borsellino N., Incorvaia L., Russo A., and Gori S.
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,Pyridines ,Receptor, ErbB-2 ,Neratinib ,Trastuzumab-emtansine ,Breast Neoplasms ,Lapatinib ,Systemic therapy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Breast cancer ,Quality of life ,Trastuzumab ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Trastuzumab deruxtecan ,HER2-positive breast cancer ,skin and connective tissue diseases ,Oxazoles ,neoplasms ,Tucatinib ,Brain Neoplasms ,business.industry ,Brain metastases ,Hematology ,medicine.disease ,030104 developmental biology ,chemistry ,Trastuzumab emtansine ,030220 oncology & carcinogenesis ,Quality of Life ,Quinazolines ,Pertuzumab ,business ,medicine.drug - Abstract
Brain metastases (BMs) are frequently associated with HER2+ breast cancer (BC). Their management is based on a multi-modal strategy including both local treatment and systemic therapy. Despite therapeutic advance, BMs still have an adverse impact on survival and quality of life and the development of effective systemic therapy to prevent and treat BMs from HER2 + BC represents an unmet clinical need. Trastuzumab-based therapy has long been the mainstay of systemic therapy and over the last two decades other HER2-targeted agents including lapatinib, pertuzumab and trastuzumab emtansine, have been introduced in the clinical practice. More recently, novel agents such as neratinib, tucatinib and trastuzumab deruxtecan have been developed, with interesting activity against BMs. Further research is needed to better elucidate the best sequence of these agents and their combination with local treatment.
- Published
- 2021
- Full Text
- View/download PDF
19. Discarded sequencing reads uncover natural variation in pest resistance in Thlaspi arvense .
- Author
-
Galanti D, Jung JH, Müller C, and Bossdorf O
- Subjects
- Animals, Disease Resistance genetics, Genome-Wide Association Study, Genetic Variation, Polymorphism, Single Nucleotide genetics, Genome, Plant genetics, Aphids genetics, Plant Diseases genetics, Plant Diseases parasitology, Plant Diseases microbiology
- Abstract
Understanding the genomic basis of natural variation in plant pest resistance is an important goal in plant science, but it usually requires large and labor-intensive phenotyping experiments. Here, we explored the possibility that non-target reads from plant DNA sequencing can serve as phenotyping proxies for addressing such questions. We used data from a whole-genome and -epigenome sequencing study of 207 natural lines of field pennycress ( Thlaspi arvense ) that were grown in a common environment and spontaneously colonized by aphids, mildew, and other microbes. We found that the numbers of non-target reads assigned to the pest species differed between populations, had significant SNP-based heritability, and were associated with climate of origin and baseline glucosinolate contents. Specifically, pennycress lines from cold and thermally fluctuating habitats, presumably less favorable to aphids, showed higher aphid DNA load, i.e., decreased aphid resistance. Genome-wide association analyses identified genetic variants at known defense genes but also novel genomic regions associated with variation in aphid and mildew DNA load. Moreover, we found several differentially methylated regions associated with pathogen loads, in particular differential methylation at transposons and hypomethylation in the promoter of a gene involved in stomatal closure, likely induced by pathogens. Our study provides first insights into the defense mechanisms of Thlaspi arvense , a rising crop and model species, and demonstrates that non-target whole-genome sequencing reads, usually discarded, can be leveraged to estimate intensities of plant biotic interactions. With rapidly increasing numbers of large sequencing datasets worldwide, this approach should have broad application in fundamental and applied research., Competing Interests: DG, JJ, CM, OB No competing interests declared, (© 2024, Galanti et al.)
- Published
- 2024
- Full Text
- View/download PDF
20. The evolutionary consequences of interactions between the epigenome, the genome and the environment.
- Author
-
Baduel P, Sammarco I, Barrett R, Coronado-Zamora M, Crespel A, Díez-Rodríguez B, Fox J, Galanti D, González J, Jueterbock A, Wootton E, and Harney E
- Abstract
The epigenome is the suite of interacting chemical marks and molecules that helps to shape patterns of development, phenotypic plasticity and gene regulation, in part due to its responsiveness to environmental stimuli. There is increasing interest in understanding the functional and evolutionary importance of this sensitivity under ecologically realistic conditions. Observations that epigenetic variation abounds in natural populations have prompted speculation that it may facilitate evolutionary responses to rapid environmental perturbations, such as those occurring under climate change. A frequent point of contention is whether epigenetic variants reflect genetic variation or are independent of it. The genome and epigenome often appear tightly linked and interdependent. While many epigenetic changes are genetically determined, the converse is also true, with DNA sequence changes influenced by the presence of epigenetic marks. Understanding how the epigenome, genome and environment interact with one another is therefore an essential step in explaining the broader evolutionary consequences of epigenomic variation. Drawing on results from experimental and comparative studies carried out in diverse plant and animal species, we synthesize our current understanding of how these factors interact to shape phenotypic variation in natural populations, with a focus on identifying similarities and differences between taxonomic groups. We describe the main components of the epigenome and how they vary within and between taxa. We review how variation in the epigenome interacts with genetic features and environmental determinants, with a focus on the role of transposable elements (TEs) in integrating the epigenome, genome and environment. And we look at recent studies investigating the functional and evolutionary consequences of these interactions. Although epigenetic differentiation in nature is likely often a result of drift or selection on stochastic epimutations, there is growing evidence that a significant fraction of it can be stably inherited and could therefore contribute to evolution independently of genetic change., Competing Interests: The authors have no conflict of interest to declare., (© 2024 The Author(s). Evolutionary Applications published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
21. DNA methylation in the wild: epigenetic transgenerational inheritance can mediate adaptation in clones of wild strawberry (Fragaria vesca).
- Author
-
Sammarco I, Díez Rodríguez B, Galanti D, Nunn A, Becker C, Bossdorf O, Münzbergová Z, and Latzel V
- Subjects
- Humans, Epigenesis, Genetic, Phenotype, Plants genetics, Clone Cells, DNA Methylation genetics, Fragaria genetics
- Abstract
Due to the accelerating climate change, it is crucial to understand how plants adapt to rapid environmental changes. Such adaptation may be mediated by epigenetic mechanisms like DNA methylation, which could heritably alter phenotypes without changing the DNA sequence, especially across clonal generations. However, we are still missing robust evidence of the adaptive potential of DNA methylation in wild clonal populations. Here, we studied genetic, epigenetic and transcriptomic variation of Fragaria vesca, a predominantly clonally reproducing herb. We examined samples from 21 natural populations across three climatically distinct geographic regions, as well as clones of the same individuals grown in a common garden. We found that epigenetic variation was partly associated with climate of origin, particularly in non-CG contexts. Importantly, a large proportion of this variation was heritable across clonal generations. Additionally, a subset of these epigenetic changes affected the expression of genes mainly involved in plant growth and responses to pathogen and abiotic stress. These findings highlight the potential influence of epigenetic changes on phenotypic traits. Our findings indicate that variation in DNA methylation, which can be environmentally inducible and heritable, may enable clonal plant populations to adjust to their environmental conditions even in the absence of genetic adaptation., (© 2023 The Authors New Phytologist © 2023 New Phytologist Foundation.)
- Published
- 2024
- Full Text
- View/download PDF
22. Transposon dynamics in the emerging oilseed crop Thlaspi arvense.
- Author
-
Contreras-Garrido A, Galanti D, Movilli A, Becker C, Bossdorf O, Drost HG, and Weigel D
- Subjects
- Humans, Retroelements genetics, Epigenesis, Genetic, Plant Breeding, Genetic Drift, DNA Transposable Elements genetics, Evolution, Molecular, Nuclear Proteins genetics, Thlaspi genetics, Thlaspi metabolism
- Abstract
Genome evolution is partly driven by the mobility of transposable elements (TEs) which often leads to deleterious effects, but their activity can also facilitate genetic novelty and catalyze local adaptation. We explored how the intraspecific diversity of TE polymorphisms might contribute to the broad geographic success and adaptive capacity of the emerging oil crop Thlaspi arvense (field pennycress). We classified the TE inventory based on a high-quality genome assembly, estimated the age of retrotransposon TE families and comprehensively assessed their mobilization potential. A survey of 280 accessions from 12 regions across the Northern hemisphere allowed us to quantify over 90,000 TE insertion polymorphisms (TIPs). Their distribution mirrored the genetic differentiation as measured by single nucleotide polymorphisms (SNPs). The number and types of mobile TE families vary substantially across populations, but there are also shared patterns common to all accessions. Ty3/Athila elements are the main drivers of TE diversity in T. arvense populations, while a single Ty1/Alesia lineage might be particularly important for transcriptome divergence. The number of retrotransposon TIPs is associated with variation at genes related to epigenetic regulation, including an apparent knockout mutation in BROMODOMAIN AND ATPase DOMAIN-CONTAINING PROTEIN 1 (BRAT1), while DNA transposons are associated with variation at the HSP19 heat shock protein gene. We propose that the high rate of mobilization activity can be harnessed for targeted gene expression diversification, which may ultimately present a toolbox for the potential use of transposition in breeding and domestication of T. arvense., Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: D.W. holds equity in Computomics, which advises breeders. D.W. advises KWS SE, a plant breeder and seed producer. All the other authors have declared that no competing interests exist. , (Copyright: © 2024 Contreras-Garrido et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2024
- Full Text
- View/download PDF
23. Stereotactic body radiotherapy in oligoprogressive metastatic castration-resistant prostate cancer during abiraterone or enzalutamide.
- Author
-
La Vecchia M, Fazio I, Borsellino N, Lo Casto A, and Galanti D
- Subjects
- Male, Humans, Receptors, Androgen therapeutic use, Retrospective Studies, Prospective Studies, Nitriles therapeutic use, Treatment Outcome, Prostatic Neoplasms, Castration-Resistant drug therapy, Prostatic Neoplasms, Castration-Resistant radiotherapy, Radiosurgery, Antineoplastic Agents therapeutic use
- Abstract
Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents., Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogressive sites, preserving the androgen receptor targeted agents. Further stereotactic body radiotherapy upon new metastatic sites was permitted. Patients showing visceral metastases or receiving palliative radiotherapy were excluded. Progressive disease at >5 metastatic sites or the appearance of visceral metastases led to a change of the systemic treatment. Primary endpoints were 36-month survival rate and 36-month rate of patients receiving treatment with androgen receptor targeted agents. Secondary endpoints were local disease control, biochemical response and safety., Results: We analyzed data from 30 patients. The 36-month survival rate was 90% (27 patients); 36-month rate of patients who were still on treatment with androgen receptor targeted agents was 50%. 20 of 30 patients had performed imaging control after a single course of stereotactic body radiotherapy: overall response rate was 50%, while clinical benefit was 93%. No ⩾G2 adverse events related to stereotactic body radiotherapy were recorded., Conclusions: Stereotactic body radiotherapy in oligoprogressive metastatic sites during androgen receptor targeted agent treatment resulted in a feasible and effective treatment to delay the start of next-line systemic treatment and prolong overall survival in metastatic castration resistant prostate cancer. Longer follow-up and further prospective studies are necessary to confirm our preliminary results.
- Published
- 2023
- Full Text
- View/download PDF
24. Genetic and environmental drivers of large-scale epigenetic variation in Thlaspi arvense.
- Author
-
Galanti D, Ramos-Cruz D, Nunn A, Rodríguez-Arévalo I, Scheepens JF, Becker C, and Bossdorf O
- Subjects
- DNA Transposable Elements, Biofuels, Plant Breeding, DNA Methylation genetics, Epigenesis, Genetic, DNA, Intergenic, Genetic Variation, Thlaspi genetics
- Abstract
Natural plant populations often harbour substantial heritable variation in DNA methylation. However, a thorough understanding of the genetic and environmental drivers of this epigenetic variation requires large-scale and high-resolution data, which currently exist only for a few model species. Here, we studied 207 lines of the annual weed Thlaspi arvense (field pennycress), collected across a large latitudinal gradient in Europe and propagated in a common environment. By screening for variation in DNA sequence and DNA methylation using whole-genome (bisulfite) sequencing, we found significant epigenetic population structure across Europe. Average levels of DNA methylation were strongly context-dependent, with highest DNA methylation in CG context, particularly in transposable elements and in intergenic regions. Residual DNA methylation variation within all contexts was associated with genetic variants, which often co-localized with annotated methylation machinery genes but also with new candidates. Variation in DNA methylation was also significantly associated with climate of origin, with methylation levels being lower in colder regions and in more variable climates. Finally, we used variance decomposition to assess genetic versus environmental associations with differentially methylated regions (DMRs). We found that while genetic variation was generally the strongest predictor of DMRs, the strength of environmental associations increased from CG to CHG and CHH, with climate-of-origin as the strongest predictor in about one third of the CHH DMRs. In summary, our data show that natural epigenetic variation in Thlaspi arvense is significantly associated with both DNA sequence and environment of origin, and that the relative importance of the two factors strongly depends on the sequence context of DNA methylation. T. arvense is an emerging biofuel and winter cover crop; our results may hence be relevant for breeding efforts and agricultural practices in the context of rapidly changing environmental conditions., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2022
- Full Text
- View/download PDF
25. New dosimetric parameters to predict ano-rectal toxicity during radiotherapy treatment.
- Author
-
Sanfratello A, Cusumano D, Piras A, Boldrini L, D'Aviero A, Fricano P, Messina M, Vaglica M, Galanti D, Spada M, Martorana G, Arena G, Angileri T, and Daidone A
- Subjects
- Humans, Quality of Life, Radiotherapy Dosage, Rectum, Retrospective Studies, Proctitis etiology, Radiation Injuries etiology, Radiation Injuries prevention & control, Rectal Neoplasms radiotherapy
- Abstract
Purpose: Radiotherapy is essential in the treatment of locally advanced rectal cancer. Side effects of radiotherapy in the treatment of rectal cancer have a great effect on quality of life. The aim of this retrospective study is to evaluate the correlation between dosimetric parameters and acute toxicity in rectal cancer patients., Methods: We analyzed the Dose Volume Histogram parameters for both the target structures and the Organs at risk of 89 patients. A dedicated statistical analysis was performed for all the acute toxicities showing a frequency rate higher than 20%. A linear logistic regression model was elaborated using the variable showing the highest level of significance at the univariate analysis., Results: The occurrence of proctitis was significantly correlated with three dosimetric parameters: D98% of low ano-rectum, D
98% and Dmean of low ano-rectum wall. A predictive linear logistic regression model reports that the D98% of the wall of the low ano-rectum must be < 38.5 Gy to decrease the rate of proctitis. A general analysis on grade 2 acute toxicity occurrence reported that it was correlated with D98% of low ano rectum., Conclusions: Two dose constraints were elaborated: D98%<33.5 Gy for low ano rectum to prevent grade 2 acute toxicity and D98%<25 Gy for low ano-rectum wall to prevent proctitis (grade 1 or superior)., (Copyright © 2022 Associazione Italiana di Fisica Medica e Sanitaria. Published by Elsevier Ltd. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF
26. Achieving Consensus for Management of Hormone-Sensitive, Low-Volume Metastatic Prostate Cancer in Italy.
- Author
-
Verzoni E, Pappagallo G, Alongi F, Arcangeli S, Francolini G, Galanti D, Galli L, Maruzzo M, Rossetti S, Siepe G, Triggiani L, Zucali PA, and D'Angelillo RM
- Subjects
- Androgen Antagonists therapeutic use, Hormones, Humans, Italy, Male, Prostatic Neoplasms pathology, Prostatic Neoplasms therapy
- Abstract
Metastatic hormone-sensitive prostate cancer (mHSPC) is usually categorized as high- or low-volume disease. This is relevant because low- and high-volume metastatic disease are associated with different outcomes, and thus management of the two forms should differ. Although some definitions have been reported, the concept of oligometastatic disease is not so clearly defined, giving rise to further variability in the choice of treatment, mainly between systemic agents and radiotherapy, especially in the era of metastasis-directed therapy. With the aim of providing clinicians with guidance on best practice, a group of medical and radiation oncologists, experts in prostate cancer, used the round robin method to generate a series of consensus statements on management of low-volume mHSPC. Consensus was obtained on three major areas of controversy: (1) with regard to clinical definitions of mHSPC, it was held that oligometastatic and low-volume disease refer to different concepts and should not be used interchangeably; (2) regarding therapy of de novo low-volume metastatic disease, androgen deprivation therapy alone can be considered undertreatment, and all patients should be evaluated for systemic treatment combinations; local therapy should not be denied in patients with mHSPC, regardless of the intensity of systemic therapy, and metastasis-directed therapy can be proposed in selected cases; (3) with regard to treatment of metachronous metastatic disease, patients should be evaluated for systemic treatment combinations. Metastasis-directed therapy can be proposed to delay systemic treatment in selected cases, especially if prostate-specific membrane antigen positron emission tomography staging has been performed and when indolent disease occurs. It is hoped that clinicians treating patients with mHSPC in daily practice will find this expert opinion of value.
- Published
- 2022
- Full Text
- View/download PDF
27. Megestrol Acetate for Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer: An Old Answer for a New Problem.
- Author
-
La Vecchia M, Galanti D, Fazio I, Paratore R, and Borsellino N
- Abstract
Prostate cancer is the most frequent malignant tumor in male. Despite its incidence increased in the last few years, the mortality is gradually decreasing, even in patients with metastatic prostate cancer (mPC). Unfortunately, prolongation of survival leads to the exhaustion of therapeutic chances. Therefore, patients with good performance status (PS) may remain out of further active treatments. We report the clinical case of a 71-year-old patient with symptomatic metastatic castration-resistant prostate cancer (mCRPC) and good PS who progressed after multiple treatments and started a hormonal therapy with megestrol acetate (MA). MA is a synthetic progestin used for treatment of mPC in 1990s since it was shown to have an antiandrogen activity. In our case, MA managed to overcome resistance to androgen receptor-targeted agents (ARTAs), getting a dramatic biochemical and radiological response and a rapid improvement of symptoms. Our clinical case shows that MA is an interesting therapeutic option especially in long-survivor patients with mCRPC and a long progression-free survival during ARTAs therapies., Competing Interests: The authors have no conflicts of interest to declare., (Copyright © 2022 by S. Karger AG, Basel.)
- Published
- 2022
- Full Text
- View/download PDF
28. The EpiDiverse Plant Epigenome-Wide Association Studies (EWAS) Pipeline.
- Author
-
Can SN, Nunn A, Galanti D, Langenberger D, Becker C, Volmer K, Heer K, Opgenoorth L, Fernandez-Pozo N, and Rensing SA
- Abstract
Bisulfite sequencing is a widely used technique for determining DNA methylation and its relationship with epigenetics, genetics, and environmental parameters. Various techniques were implemented for epigenome-wide association studies (EWAS) to reveal meaningful associations; however, there are only very few plant studies available to date. Here, we developed the EpiDiverse EWAS pipeline and tested it using two plant datasets, from P. abies (Norway spruce) and Q. lobata (valley oak). Hence, we present an EWAS implementation tested for non-model plant species and describe its use.
- Published
- 2021
- Full Text
- View/download PDF
29. NEPA as antiemetic prophylaxis after failure of 5HT 3 -RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocentric real-life experience.
- Author
-
Valerio MR, Gebbia V, Borsellino N, Vecchia M, Serretta V, Pardo S, Cipolla C, and Galanti D
- Subjects
- Adult, Carboplatin administration & dosage, Carboplatin adverse effects, Deoxycytidine administration & dosage, Deoxycytidine adverse effects, Deoxycytidine analogs & derivatives, Female, Humans, Male, Middle Aged, Nausea chemically induced, Palonosetron administration & dosage, Pyridines administration & dosage, Retrospective Studies, Treatment Failure, Vomiting chemically induced, Gemcitabine, Antiemetics administration & dosage, Dexamethasone administration & dosage, Drug Therapy, Combination adverse effects, Nausea prevention & control, Pre-Exposure Prophylaxis methods, Serotonin 5-HT3 Receptor Antagonists administration & dosage, Vomiting prevention & control
- Abstract
Introduction: Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients' quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK
1 -RA and palonosetron, a 5HT3 -RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist., Methods: Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastatic non-small cell lung cancer (NSCLC), ovarian cancer or urothelial cancer and experienced nausea and/or vomiting after the first cycle of chemotherapy, despite an antiemetic prophylaxis with a 5HT3 -RA and dexamethasone. Primary efficacy endpoint was complete response (CR: no emesis, no rescue medication) obtained with NEPA, during the overall phase (0-120 h), after the start of chemotherapy., Results: During the first cycle of chemotherapy, 15 out of 30 (50%) patients did not properly control CINV with a 5HT3 -RA plus dexamethasone used as primary antiemetic prophylaxis and then were switched to NEPA from the subsequent cycle. During NEPA administration, 13 out of 15 patients (86.7%) achieved an overall CR (no emesis, no rescue medication). Antiemetic treatment with NEPA was very well tolerated with only two patients (13.3%) that experienced a grade 1 TEAE., Conclusions: Our experience showed that NEPA has proven to be very effective and well tolerated in the prophylaxis of CINV induced by carboplatin-based chemotherapy.- Published
- 2021
- Full Text
- View/download PDF
30. The HERBA Study: A Retrospective Multi-Institutional Italian Study on Patients With Brain Metastases From HER2-Positive Breast Cancer.
- Author
-
Gori S, Puglisi F, Moroso S, Fabi A, La Verde N, Frassoldati A, Tarenzi E, Garrone O, Vici P, Laudadio L, Cretella E, Turazza M, Foglietta J, Leonardi V, Cavanna L, Barni S, Galanti D, Russo A, Marchetti F, Valerio M, Lunardi G, Alongi F, and Inno A
- Subjects
- Adult, Aged, Breast Neoplasms metabolism, Breast Neoplasms pathology, Combined Modality Therapy, Female, Follow-Up Studies, Humans, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Prognosis, Retrospective Studies, Survival Rate, Biomarkers, Tumor metabolism, Breast Neoplasms therapy, Neoplasm Recurrence, Local therapy, Receptors, Estrogen metabolism
- Abstract
Background: There is no sufficient evidence to establish a standard of care for patients with brain metastases (BM) from HER2
+ breast cancer (BC). The aim of this study was to assess the impact of local and systemic treatments on the outcome of patients diagnosed with BM from HER2+ BC over a period of 10 years, from 2005 to 2014., Patients and Methods: Data of 154 patients were retrospectively collected at 14 Italian institutions through a specifically designed database., Results: Median overall survival (OS) was 24.5 months. Patients receiving surgery/stereotactic radiosurgery experienced longer OS compared to those receiving whole-brain radiotherapy or no treatment (33.5 vs. 11.4 months; hazard ratio = 0.34; 95% confidence interval, 0.22-0.52; P < .001). Interestingly, whole-brain radiotherapy did not improve OS compared to no treatment (11.4 vs. 9.8 months; hazard ratio = 0.99; 95% confidence interval, 0.62-1.62; P = .99). HER2-targeted therapy was associated with better OS compared to systemic therapy without HER2-targeted therapy or no systemic therapy (27.5 vs. 5.4 months; hazard ratio = 0.26; 95% confidence interval, 0.17-0.41; P < .001). At multivariate analysis stratified by local treatments, systemic therapy, Karnofsky performance status, and neurologic symptoms significantly affected OS. Age, number of BM, steroid therapy, number of previous lines of systemic therapy, status of extracranial disease, and period of diagnosis had no significant impact on OS., Conclusion: Patients with BM from HER2+ BC treated with surgery/stereotactic radiosurgery as local treatment and HER2-targeted therapy as systemic treatment experienced the best outcomes. Patients with low Karnofsky performance status and neurologic symptoms had poor survival., (Copyright © 2019 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
31. Erratum to "Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy".
- Author
-
Genova P, Sorce M, Cabibi D, Genova G, Gebbia V, Galanti D, Ancona C, and Valerio MR
- Abstract
[This corrects the article DOI: 10.1155/2017/2079068.].
- Published
- 2018
- Full Text
- View/download PDF
32. Gastric and Rectal Metastases from Malignant Melanoma Presenting with Hypochromic Anemia and Treated with Immunotherapy.
- Author
-
Genova P, Sorce M, Cabibi D, Genova G, Gebbia V, Galanti D, Galanti D, Ancona C, and Valerio MR
- Abstract
The authors present a case of an 80-year-old Caucasian male with multiple gastric and rectal metastases from malignant melanoma presenting with hypochromic anemia as the sole symptom of disease without evidence of cutaneous and ocular tumor localization. The patient had a medical history positive for malignant lentigo melanoma of the occipital region of the scalp and early stage laryngeal squamous cell carcinoma and prostatic carcinoma treated with radiation therapy. The authors make some considerations on intestinal involvement by metastatic melanoma and discuss the choice of not treating with endoscopic procedures the gastric metastatic lesions most likely responsible for the clinical sign present at diagnosis. The patient was referred to clinical oncologists and received immunotherapy with ipilimumab and pembrolizumab.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.